Pheochromocytomas and secreting paragangliomas

Orphanet Journal of Rare Diseases

Volumn 1, Issue 1, 2006, Pages

  Plouin, Pierre François ^a,b   Gimenez Roqueplo, Anne Paule ^a,b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b PGLNET Networks   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOLAMINE; PROTEIN RET; RET PROTEIN, HUMAN;

ADRENAL DISEASE; ADRENAL TUMOR; BIOSYNTHESIS; CHEMODECTOMA; DIFFERENTIAL DIAGNOSIS; GENETIC SCREENING; GENETICS; HUMAN; HYPERTENSION; METHODOLOGY; PHEOCHROMOCYTOMA; PROGNOSIS; REVIEW; SECRETION;

ADRENAL GLAND DISEASES; ADRENAL GLAND NEOPLASMS; CATECHOLAMINES; DIAGNOSIS, DIFFERENTIAL; GENETIC SCREENING; HUMANS; HYPERTENSION; PARAGANGLIOMA, EXTRA-ADRENAL; PHEOCHROMOCYTOMA; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-RET;

EID: 34248187746     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-1-49     Document Type: Review

References (29)

1. Pheochromocytoma: state-of-the-art and future prospects. EL Bravo R Tagle, Endocr Rev 2003 24 539 553 10.1210/er.2002-0013 12920154
2. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. K Pacak WM Linehan G Eisenhofer MM Walther DS Goldstein, Ann Intern Med 2001 134 315 329 11182843
3. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. G Eisenhofer DS Goldstein MM Walther P Friberg JW Lenders HR Keiser K Pacak, J Clin Endocrinol Metab 2003 88 2656 2666 10.1210/jc.2002-030005 12788870
4. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. F Mantero M Terzolo G Arnaldi G Osella AM Masini A Ali M Giovagnetti G Opocher A Angeli, J Clin Endocrinol Metab 2000 85 637 644 10.1210/jc.85.2.637 10690869
5. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. HP Neumann C Pawlu M Peczkowska B Bausch SR McWhinney M Muresan M Buchta G Franke J Klisch TA Bley S Hoegerle CC Boedeker G Opocher J Schipper A Januszewicz C Eng European-American Paraganglioma Study Group, JAMA 2004 292 943 951 10.1001/jama.292.8.943 15328326
6. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. DE Benn AP Gimenez-Roqueplo JR Reilly J Bertherat J Burgess K Byth M Croxson PL Dahia M Elston O Gimm D Henley P Herman V Murday P Niccoli-Sire JL Pasieka V Rohmer K Tucker X Jeunemaitre DJ Marsh PF Plouin BG Robinson, J Clin Endocrinol Metab 2006 91 827 836 10.1210/jc.2005-1862 16317055
7. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. L Amar A Servais AP Gimenez-Roqueplo F Zinzindohoue G Chatellier PF Plouin, J Clin Endocrinol Metab 2005 90 2110 2116 10.1210/jc.2004-1398 15644401
8. RET and neuroendocrine tumors. M Ichihara Y Murakumo M Takahashi, Cancer Lett 2004 204 197 211 10.1016/S0304-3835(03)00456-7 15013219
9. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. AP Gimenez-Roqueplo J Favier P Rustin JJ Mourad PF Plouin P Corvol A Rotig X Jeunemaitre, Am J Hum Genet 2001 69 1186 1197 11605159 10.1086/324413
10. Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. AP Gimenez-Roqueplo J Favier P Rustin C Rieubland V Kerlan PF Plouin A Rotig X Jeunemaitre, J Clin Endocrinol Metab 2002 87 4771 4774 10.1210/jc.2002-020525 12364472
11. Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. J Favier PF Plouin P Corvol JM Gasc, Am J Pathol 2002 161 1235 1246 12368197
12. Role of VHL gene mutation in human cancer. WY Kim WG Kaelin, J Clin Oncol 2004 22 4991 5004 10.1200/JCO.2004.05.061 15611513
13. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. MA Selak SM Armour ED MacKenzie H Boulahbel DG Watson KD Mansfield Y Pan M Celeste Simon CB Thompson E Gottlieb, Cancer Cell 2005 7 77 85 10.1016/j.ccr.2004.11.022 15652751
14. The urinary metanephrine to creatinine ratio in the diagnosis of pheochromocytoma. E Héron G Chatellier E Billaud E Foos PF Plouin, Ann Intern Med 1996 125 300 303 8678394
15. Biochemical diagnosis of pheochromocytoma: which test is best? JW Lenders K Pacak MM Walther WM Linehan M Mannelli P Friberg HR Keiser DS Goldstein G Eisenhofer, JAMA 2002 287 1427 1434 10.1001/jama.287.11.1427 11903030
16. The laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience. YC Kudva AM Sawka WF Young Jr, J Clin Endocrinol Metab 2003 88 4533 4539 10.1210/jc.2003-030720 14557417
17. Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. RJ Hsiao RJ Parmer MA Takiyyuddin DT O'Connor, Medicine (Baltimore) 1991 70 33 45 1988765
18. Production, characterization, and expression of neuropeptide Y by human pheochromocytoma. P Des Senanayake J Denker EL Bravo RM Graham, J Clin Invest 1995 96 2503 2509 7593641
19. Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. PF Plouin G Chatellier I Fofol P Corvol, Hypertension 1997 29 1133 1139 9149678
20. The value of plasma markers for the clinical behaviour of phaeochromocytomas. E van der Harst WW de Herder RR de Krijger HA Bruining HJ Bonjer SW Lamberts AH van den Meiracker TH Stijnen F Boomsma, Eur J Endocrinol 2002 147 85 94 10.1530/eje.0.1470085 12088924
21. Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. I Ilias K Pacak, J Clin Endocrinol Metab 2004 89 479 491 10.1210/jc.2003-031091 14764749
22. On the association of succinate dehydrogenase mutations with hereditary paraganglioma. BE Baysal, Trends Endocrinol Metab 2003 14 453 459 10.1016/j.tem.2003.08.004 14643060
23. Germ-line mutations in nonsyndromic pheochromocytoma. HP Neumann B Bausch SR McWhinney BU Bender O Gimm G Franke J Schipper J Klisch C Altehoefer K Zerres A Januszewicz C Eng WM Smith R Munk T Manz S Glaesker TW Apel M Treier M Reineke MK Walz C Hoang-Vu M Brauckhoff A Klein-Franke P Klose H Schmidt M Maier-Woelfle M Peczkowska C Szmigielski C Eng Freiburg-Warsaw-Columbus Pheochromocytoma Study Group, N Engl J Med 2002 346 1459 1466 10.1056/NEJMoa020152 12000816
24. Genetic testing in pheochromocytoma or functional paraganglioma. L Amar J Bertherat E Baudin C Ajzenberg B Bressac de Paillerets O Chabre B Chamontin B Delemer S Giraud A Murat P Niccoli-Sire S Richard V Rohmer JL Sadoul L Strompf M Schlumberger X Bertagna PF Plouin X Jeunemaitre AP Gimenez-Roqueplo, J Clin Oncol 2005 23 8812 8818 10.1200/JCO.2005.03.1484 16314641
25. The genetic basis of pheochromocytoma: who to screen and how? PF Plouin AP Gimenez-Roqueplo, Nat Clin Pract Endocrinol Metab 2006 2 60 61 10.1038/ncpendmet0097 16932255
26. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. AP Gimenez-Roqueplo J Favier P Rustin C Rieubland M Crespin V Nau P Khau Van Kien P Corvol PF Plouin X Jeunemaitre COMETE Network, Cancer Res 2003 63 5615 5621 14500403
27. Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. PF Plouin JM Duclos F Soppelsa G Boublil G Chatellier, J Clin Endocrinol Metab 2001 86 1480 1486 10.1210/jc.86.4.1480 11297571
28. New therapeutic and surgical approaches for sporadic and hereditary pheochromocytoma. MM Walther, Ann N Y Acad Sci 2002 970 41 53 12381540
29. Malignant pheochromocytoma: current status and initiatives for future progress. G Eisenhofer SR Bornstein FM Brouwers NK Cheung PL Dahia RR de Krijger TJ Giordano LA Greene DS Goldstein H Lehnert WM Manger JM Maris HP Neumann K Pacak BL Shulkin DI Smith AS Tischler WF Young Jr, Endocr Relat Cancer 2004 11 423 436 10.1677/erc.1.00829 15369446